Health Research Authority

Specialist Adhoc REC

Please note: This is the favourable opinion of the REC only and does not allow you to start your study at NHS sites in England until you receive HRA Approval

07 September 2022

Professor Christopher Chiu
Professor of Infectious Diseases
Imperial College London
Department of Infectious Diseases,
Room 8N15, 8th Floor, Commonwealth Building,
Hammersmith Hospital
W12 0NN

Dear Professor Chiu

Study title:	**Development of a SARS-CoV-2 Delta variant human infection challenge model (COVHIC002)**
REC reference:	**22/UK/0001**
Protocol number:	**21HH7162**
IRAS project ID:	**318173**

Thank you for your letter of 06 September 20222, responding to the Research Ethics Committee's (REC) request for further information on the above research and submitting revised documentation.

The further information has been considered on behalf of the Committee by the Chair and [redacted].

Confirmation of ethical opinion

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation

as revised, subject to the conditions specified below.

Good practice principles and responsibilities

The UK Policy Framework for Health and Social Care Research sets out principles of good practice in the management and conduct of health and social care research. It also outlines the responsibilities of individuals and organisations, including those related to the four elements of research transparency:

1. registering research studies
2. reporting results
3. informing participants
4. sharing study data and tissue

Conditions of the favourable opinion

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

Confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS management permission (in Scotland) should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).

Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS permission for research is available in the Integrated Research Application System.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations

Registration of Clinical Trials

All research should be registered in a publicly accessible database and we expect all researchers, research sponsors and others to meet this fundamental best practice standard.

It is a condition of the REC favourable opinion that **all clinical trials are registered** on a publicly accessible database within six weeks of recruiting the first research participant. For this purpose, 'clinical trials' are defined as:

- clinical trial of an investigational medicinal product
- clinical investigation or other study of a medical device
- combined trial of an investigational medicinal product and an investigational medical device

- other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice.

Failure to register a clinical trial is a breach of these approval conditions, unless a deferral has been agreed by the HRA (for more information on registration and requesting a deferral see: Research registration and research project identifiers).

If you have not already included registration details in your IRAS application form you should notify the REC of the registration details as soon as possible.

Publication of Your Research Summary

We will publish your research summary for the above study on the research summaries section of our website, together with your contact details, no earlier than three months from the date of this favourable opinion letter.

Should you wish to provide a substitute contact point, make a request to defer, or require further information, please visit:
https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/

N.B. If your study is related to COVID-19 we will aim to publish your research summary within 3 days rather than three months.

During this public health emergency, it is vital that everyone can promptly identify all relevant research related to COVID-19 that is taking place globally. If you haven't already done so, please register your study on a public registry as soon as possible and provide the REC with the registration detail, which will be posted alongside other information relating to your project. We are also asking sponsors not to request deferral of publication of research summary for any projects relating to COVID-19. In addition, to facilitate finding and extracting studies related to COVID-19 from public databases, please enter the WHO official acronym for the coronavirus disease (COVID-19) in the full title of your study. Approved COVID-19 studies can be found at:
https://www.hra.nhs.uk/covid-19-research/approved-covid-19-research/

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

After ethical review: Reporting requirements

The attached document "After ethical review – guidance for researchers" gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study, including early termination of the study

- Final report
- Reporting results

The latest guidance on these topics can be found at https://www.hra.nhs.uk/approvals-amendments/managing-your-approval/.

Ethical review of research sites

NHS/HSC sites

The favourable opinion applies to all NHS/HSC sites taking part in the study, subject to confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or management permission (in Scotland) being obtained from the NHS/HSC R&D office prior to the start of the study (see "Conditions of the favourable opinion" below).

Non-NHS/HSC sites

I am pleased to confirm that the favourable opinion applies to any non-NHS/HSC sites listed in the application, subject to site management permission being obtained prior to the start of the study at the site.

Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

Document	*Version*	*Date*
Copies of materials calling attention of potential participants to the research [COVHIC002_Poster One_V1.0_28.06.2022]	1.0	28 June 2022
Copies of materials calling attention of potential participants to the research [COVHIC002_Poster Three_V1.0_28.06.2022]	1.0	28 June 2022
Copies of materials calling attention of potential participants to the research [COVHIC002_Poster Two_V1.0_28.06.2022]	1.0	28 June 2022
Copies of materials calling attention of potential participants to the research [COVHIC002_Advertising_Text_V1.1_11.08.2022_Clean]	1.1	11 August 2022
Copies of materials calling attention of potential participants to the research [COVHIC002_Advertising_Text_V1.1_11.08.2022_TC]	1.1	11 August 2022
Copies of materials calling attention of potential participants to the research [COVHIC002_Website_Text_V1.1_11.08.2022_Clean]	1.1	11 August 2022
Copies of materials calling attention of potential participants to the research [COVHIC002_Website_Text_V1.1_11.08.2022_TC]	1.1	11 August 2022
Covering letter on headed paper [COVHIC002_REC_Cover Letter_First_Submission_28.06.2022]	1.0	28 June 2022
Covering letter on headed paper [COVHIC002_REC_Cover Letter_in_response_30.08.2022]	2	30 August 2022
Covering letter on headed paper [COVHIC002_REC_Cover Letter_in_second_response_06.09.2022]	3	06 September 2022
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [Imperial College London - CT VOI 2021]	1.0	01 August 2021
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [Updated insurance]		01 August 2022
GP/consultant information sheets or letters [COVHIC002_GP_Summary_Request_V1.0_28.06.2022]	1.0	28 June 2022

GP/consultant information sheets or letters [COVHIC002_GP_Enrolment_Letter_V1.0_28.06.2022]	1.0	28 June 2022
GP/consultant information sheets or letters [COVHIC002_GP_Interim_FU_Letter_V1.0_28.06.2022]	1.0	28 June 2022
GP/consultant information sheets or letters [COVHIC002_GP_End_Of_Study_Letter_V1.0_28.06.2022]	1.0	28 June 2022
IRAS Application Form [IRAS_Form_04082022]		04 August 2022
IRAS Application Form XML file [IRAS_Form_04082022]		04 August 2022
IRAS Checklist XML [Checklist_04082022]		04 August 2022
IRAS Checklist XML [Checklist_06092022]		06 September 2022
Letter from funder [Award Letter 225170_Z_22_Z_Chiu]		08 June 2022
Letter from sponsor [Sponsor Letter 21HH7162]	1.0	01 August 2022
Letters of invitation to participant [COVHIC002_Invitation_Letter_V1.0_28.06.2022]	1.0	28 June 2022
Letters of invitation to participant [COVHIC002_Visit_Invitation_Letters_V1.0_28.06.2022]	1.0	28 June 2022
Letters of invitation to participant [COVHIC002_Quarantine_Invitation_Letter_V1.1_11.08.2022_Clean]	1.1	11 August 2022
Letters of invitation to participant [COVHIC002_Quarantine_Invitation_Letter_V1.1_11.08.2022_TC]	1.1	11 August 2022
Other [COVHIC002_Cognitive_Tasks_V1.0_28.06.2022]	1.0	28 June 2022
Other [COVHIC002_Consent_Quiz_V1.0_28.06.2022]	1.0	28 June 2022
Other [COVHIC002_Contact_Card_V1.0_28.06.2022]	1.0	28 June 2022
Other [COVHIC002_Typical_Day_Summary_V1.0_28.06.2022]	1.0	28 June 2022
Other [COVHIC002_Follow_Up_Letter_V1.0_28.06.2022]	1.0	28 June 2022
Other [COVHIC002_Stool_Swab_Instructions_V1.0_28.06.2022]	1.0	28 June 2022
Other [Certificate of Compliance cGMP Delta Master Virus Bank Intermediate 21-hVIVO-400]		20 May 2022
Other [Certificate of Compliance cGMP Delta Inoculum 21-hVIVO-401]		20 May 2022
Other [QP Statement cGMP Delta Master Virus Bank 21-hVIVO-400]		01 February 2021
Other [QP Statement cGMP Delta Inoculum 21-hVIVO-401]		01 February 2021
Other [NON-INVESTIGATIONAL MEDICINAL PRODUCT DOSSIER cGMP SARS-CoV-2/Wuhan Human Challenge Virus]	1.0	11 April 2022
Other [Paxlovid SmPC 02.03.2022]		02 March 2022
Other [Lagevrio SmPC 01.04.2022]		01 April 2022
Other [Veklury SmPC 10.01.2022]		10 January 2022
Other [COVHIC002_DSMB_Charter_V1.0_28.06.2022]	1.0	28 June 2022
Other [COVHIC002_Delegation_Log_V1.0_28.06.2022]	1.0	28 June 2022
Other [27.01.22 Insight report Human Challenge with Coronavirus with Delta Discussion Group - Final]		27 January 2022
Other [PI_Anika Singanayagam_CV_31.03.2022]		31 March 2022
Other [PI_Margherita Bracchi_CV_18.05.2021]		18 May 2021
Other [COVHIC002_Employer_Info_Sheet_V1.1_11.08.2022_Clean]	1.1	11 August 2022

Other [COVHIC002_Protocol_V1.1_11.08.2022_TC]	1.1	11 August 2022
Other [COVHIC002_Employer_Info_Sheet_V1.1_11.08.2022_TC]	1.1	11 August 2022
Participant consent form [COVHIC002_Pre_Screening_ICF_V1.1_11.08.2022_Clean]	1.1	11 August 2022
Participant consent form [COVHIC002_Pre-screening_ICF_V1.1_11.08.2022_TC]	1.1	11 August 2022
Participant consent form [COVHIC002_ICF_V1.2_05.09.2022_Clean]	1.2	05 September 2022
Participant consent form [COVHIC002_ICF_V1.2_05.09.2022_TC]	1.2	05 September 2022
Participant information sheet (PIS) [COVHIC002_Summary_Of_PIS_V1.0_28.06.2022]	1.0	28 June 2022
Participant information sheet (PIS) [COVHIC002_PIS_V1.1_11.08.2022_Clean]	1.1	11 August 2022
Participant information sheet (PIS) [COVHIC002_PIS_V1.1_11.08.2022_TC]	1.1	11 August 2022
Research protocol or project proposal [COVHIC002_Protocol_V1.1_11.08.2022_Clean]	1.1	11 August 2022
Sample diary card/patient card [COVHIC002_Symptom_Diary_V1.0_28.06.2022]	1.0	28 June 2022
Summary CV for Chief Investigator (CI) [Curriculum_Vitae_Research_ChiuC_FULL_220726]		26 July 2022
Validated questionnaire [GAD-7 Questionnaire]		
Validated questionnaire [PHQ-9 Questionnaire]		

Statement of compliance

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website:
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/

HRA Learning

We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities– see details at:
https://www.hra.nhs.uk/planning-and-improving-research/learning/

IRAS project ID: 318173 Please quote this number on all correspondence

With the Committee's best wishes for the success of this project.

Yours sincerely

[redacted]

PP

[redacted]

Chair

Email: [redacted]

Enclosures: "After ethical review – guidance for researchers"

Copy to: [redacted] Imperial College London

Lead Nation approvals@hra.nhs.uk